Soufflé Therapeutics

Watertown, MA biotech developing RNA medicines, with lead programs for muscular dystrophy, heart failure and metabolic disease.

View on the globe

$135MEquity raised in 2025–20262025 — · 2026 $135M · 1 equity round
$135MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 13 Oct 2026 to 13 Oct 2026, $135M equity disclosed. Earlier rounds exist but are not sourced.13 Oct 2026: Series B, $135M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedQ2Q3Q42027Q2Q3Equity round13 Oct 2026 · Series B · $135M · led by Juvia GroupSeries B · $135M
Funding history: 1 round from 13 Oct 2026 to 13 Oct 2026, $135M equity disclosed. Earlier rounds exist but are not sourced.13 Oct 2026: Series B, $135M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourcedQ2Q3Q42027Q2Q3Equity round13 Oct 2026 · Series B · $135M · led by Juvia Group$135M

Funding history 1 round · 1 source

Earlier rounds not yet sourced. Soufflé Therapeutics raised before 13 Oct 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series B
    Amount$135M
    Post-money—
    ✓ Confirmed
    Lead
    Juvia Group
    Also
    TCG Crossover Management, BB Biotech, Fidelity, Balyasny Asset Management, Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, Invus, Janus Henderson Investors, Leaps by Bayer, Temasek
    Note
    Company release, 13 Oct 2026 (read via VentureBeat's reproduction): 'close of an oversubscribed $135 million Series B financing'. Investor list capped at 12; the release also names Polaris Partners, Safar Partners, TAS Partners and Vida Ventures, and an unnamed sovereign wealth fund. Valuation not stated. An aggregator's $125M figure conflicts with the release and is not used. HQ: release dateline reads Boston; company site footer gives a Watertown, MA address, which is used.
    Sources
  2. Earlier rounds not yet sourced

Investors 13

  • Juvia Group1
  • Amgen Ventures
  • ARCH Venture Partners
  • Balyasny Asset Management
  • BB Biotech
  • Bessemer Venture Partners
  • Breyer Capital
  • Fidelity
  • Invus
  • Janus Henderson Investors
  • Leaps by Bayer
  • TCG Crossover Management
  • Temasek

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the Watertown hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Soufflé Therapeutics and its logo are trademarks of their owners, used here for identification only.